Insulin Delivery Techniques in Diabetes Management

Effective management of diabetes hinges on precise and reliable delivery of insulin to mimic physiological secretion and maintain glycaemic control. Traditional subcutaneous injections via vial and syringe remain in widespread use, but have gradually given way to more sophisticated modalities designed to enhance dosing accuracy, patient convenience and adherence. Insulin pens, available as reusable and disposable formats, facilitate discreet and rapid dosing with reduced risk of dosing error. Continuous subcutaneous insulin infusion (CSII) systems, commonly known as insulin pumps, provide programmable basal and bolus insulin delivery, allowing finer titration of insulin to meet day-to-day variations in insulin requirements. Emerging approaches—such as microneedle patches, implantable depots and inhaled formulations—aim to overcome limitations of subcutaneous routes by offering minimally invasive, painless or non-injection-based alternatives, though most remain at preclinical or early clinical stages. Across all delivery techniques, factors such as needle size, injection site rotation and device ergonomics directly influence efficacy, safety and patient satisfaction. Ongoing research seeks to integrate smart technologies, including wireless connectivity and real-time glucose-responsive insulin release, to usher in a closed-loop era of diabetes care.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Insulin Delivery Techniques in Diabetes Management publication trend

The graph below shows the total number of articles in insulin delivery techniques in diabetes management across all publications each year (not limited to Nature Index journals).

Technical terms

Subcutaneous injection: delivering insulin into the fatty tissue beneath the skin to ensure gradual absorption.

Insulin pen: a hand-held device prefilled or refillable with insulin, offering improved dosing accuracy and convenience over syringes.

Continuous subcutaneous insulin infusion (CSII): automated pump therapy providing programmable basal and bolus insulin delivery via a cannula in subcutaneous tissue.

Lipohypertrophy: localised thickening of subcutaneous fat tissue resulting from repeated insulin injections at the same site, which can impair absorption.

References

1. Expression of concern: Innovative transdermal delivery of insulin using gelatin methacrylate-based microneedle patches in mice and mini-pigs. Nanoscale Horizons (2025).
2. The Review of Insulin Pens—Past, Present, and Look to the Future. Frontiers in Endocrinology (2022).
3. Insulin‐induced Lipohypertrophy in Patients with Type 1 Diabetes Mellitus Treated with an Insulin Pump. International Journal of Endocrinology (2022).
4. Improved insulin injection technique, treatment satisfaction and glycemic control: Results from a large cohort education study. Journal of Clinical & Translational Endocrinology (2020).